Want to see TSE:ZRO full AI Analyst Report?
Biosenta Inc (ZRO) AI Stock Analysis
Biosenta Inc
(CNQX:ZRO)
The score is primarily constrained by severe financial weakness, including persistent losses, negative equity, high debt relative to assets, and continuing cash burn. Technical positioning provides a limited offset because the price is above its moving averages, but negative MACD and the lack of earnings or dividend support keep the overall score low.
Biosenta Inc (ZRO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 2.78M
- Dividend Yield
- ―
- Average Volume (3M)
- 18.32K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.17
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 5
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Biosenta Inc Business Overview & Revenue Model
Company Description
Biosenta Inc., a Toronto-based Canadian firm established in 1986, specializes in the development, manufacturing, and sale of antimicrobial chemical compounds for both residential and commercial applications throughout the country. The company is acti...
How the Company Makes Money
Biosenta’s expected revenue model is primarily derived from commercializing its antimicrobial/odor-control technologies through product sales and/or licensing arrangements. Potential revenue streams include (1) direct sales of antimicrobial and odor-...
Biosenta Inc Financial Statement Overview
Summary
Very weak financial condition: the income statement shows persistent, disproportionate losses and gross losses, shareholders’ equity is negative and worsening, debt exceeds $7.5 million against a very small asset base, and operating and free cash flow remain negative.
Income Statement
6Very NegativeBalance Sheet
4Very NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3,647 | 1,211 | 1,379 | 1,042 | 1,151 | 168.10K |
| Gross Profit | -2,324 | -1,777 | 835 | 427 | 728 | 99.11K |
| EBITDA | -1.52M | -1.39M | -1.09M | -4.75M | -17.73K | -23.83K |
| Net Income | -2.58M | -2.51M | -2.23M | -6.30M | -1.46M | -2.05M |
Balance Sheet | ||||||
| Total Assets | 102.30K | 110.33K | 113.54K | 107.59K | 256.08K | 263.66K |
| Cash, Cash Equivalents and Short-Term Investments | 19.93K | 26.49K | 8,529 | 5,883 | 27.26K | 111.88K |
| Total Debt | 7.52M | 694.59K | 5.55M | 5.62M | 94.77K | 152.43K |
| Total Liabilities | 11.89M | 10.17M | 7.99M | 7.96M | 3.18M | 2.86M |
| Stockholders Equity | -11.78M | -10.06M | -7.88M | -7.86M | -2.92M | -2.59M |
Cash Flow | ||||||
| Free Cash Flow | -462.73K | -481.24K | -779.35K | -566.35K | -504.43K | -672.29K |
| Operating Cash Flow | -461.07K | -455.38K | -779.35K | -550.79K | -504.43K | -672.29K |
| Investing Cash Flow | -1,647 | -25.86K | 0 | -15.56K | 0 | 0 |
| Financing Cash Flow | 477.97K | 499.20K | 781.99K | 544.97K | 419.81K | 739.86K |
Biosenta Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 93.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ZRO.
Biosenta Inc Peers Comparison
Overall Rating
- TSE:ZRO45Neutral
TSE:LFST40Underperform
TSE:PSYC39Underperform
TSE:URAI39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| TSE:ZRO | 45Neutral | CAD 2.78M | -0.78 | 23.72% | ― | ― | ― |
| TSE:LFST | 40Underperform | CAD 1.33M | 8.33 | 0.38% | ― | -87.74% | -220.61% |
| TSE:PSYC | 39Underperform | CAD 2.04M | -0.29 | -196.58% | ― | 115.14% | -5.84% |
| TSE:URAI | 39Underperform | CAD 9.49M | -11.91 | -147.81% | ― | ― | -65.67% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ZRO | Biosenta Inc | 0.08 | -0.04 | -33.33% | |
| TSE:BGA | BioNeutra Global | 0.03 | 0.00 | 0.00% | |
| TSE:LFST | Lifeist Wellness Inc | 0.04 | -0.04 | -50.00% | |
| TSE:PSYC | Psyched Wellness Ltd | 0.01 | -0.01 | -50.00% | |
| TSE:MOOO.X | Happy Supplements Inc. | 0.35 | -0.05 | -12.50% | |
| TSE:URAI | Pure to Pure Beauty Inc. | 0.07 | -0.16 | -67.39% |
Biosenta Inc Corporate Events
Biosenta Begins Real-World TRUE Disinfectant Pilot with Dynamic Facility Services
PositiveBiosenta Inc. has begun real-world testing of its TRUE disinfectant with Dynamic Facility Services, deploying the product at an office building and a commercial operation to evaluate how it integrates into professional cleaning workflows and delivers...
Biosenta Launches TRUE Disinfectant Pilot with Dynamic Facility Services
PositiveBiosenta Inc. has signed a memorandum of understanding with British Columbia-based Dynamic Facility Services to run a pilot program using Biosenta’s TRUE disinfectant in Dynamic’s commercial cleaning operations. The initiative will assess...
Biosenta Highlights Tri-Filler Antimicrobial Technology in High-Level University of Calgary Visit
PositiveBiosenta Inc. showcased its Tri-Filler™ antimicrobial technology during a visit by Secretary of State (International Development) Randeep Sarai to the University of Calgary research facilities. The tour highlighted the company’s collabora...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026